In addition, Eisai must conduct a post-authorization safety study, including setting up a patient registry for the European Union. Now each European country must set its own rules for access and ...

Peter Landers is The Wall Street Journal's Asia business, finance and economics editor, based in Singapore. He previously ...

WITH Cleveland Clinic’s report of around 300 million people globally having issues with color blindness in mind, Ubisoft, a French video game publisher, publicized a color simulation tool that more or ...

Merck MRK reported first-quarter 2025 adjusted earnings per share (EPS) of $2.22, which beat the Zacks Consensus Estimate of ...

Biogen BIIB will report first-quarter 2025 results on May 1, before market open. In the last reported quarter, the company's ...

Leqembi has been approved in the European Union for the treatment of certain adults with early Alzheimer's disease and mild ...

From joint ventures to licensing deals, biotechnology is emerging as a strategic bridge between China and Japan.

The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. | The Trump administration is expected to announce tariffs on pharmaceuticals ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat ... Leqembi is also approved in Japan, China, Great Britain and several other markets.

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

The EU approval comes after Eisai and Biogen were given approval for a new once-monthly intravenous maintenance dose of ...

(RTTNews) - Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced that the European Commission has granted the amyloid-beta (A) monoclonal antibody Leqembi (lecanemab) Marketing ...